Beat Thürlimann

39.4k citations

214 papers · 17.9k indexed · 10 hit papers · h-index 57

Impact in

Cancer Research top 0.02%
- Breast Cancer Treatment Studies
Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Risks and Factors
- Bone health and treatments

Papers in

Cancer Research 122
- Breast Cancer Treatment Studies 118
Oncology 142
- Cancer Treatment and Pharmacology 49
- HER2/EGFR in Cancer Research 47
- Bone health and treatments 23
- Cancer Risks and Factors 15

Co-authors: Aron Goldhirsch Richard D. Gelber Alan S. Coates Hans-Jörg Senn W. C. Wood Karen N. Price Monica Castiglione‐Gertsch Marco Colleoni
Journals: Annals of Oncology (44 papers)Journal of Clinical Oncology (42 papers)European Journal of Cancer (17 papers)The Breast (13 papers)Breast Cancer Research and Treatment (13 papers)
Partner nations: Switzerland United States Italy

In The Last Decade

Beat Thürlimann

211 papers receiving 17.4k citations

Hit Papers

10 papers align trajectories log scale

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 2019 · 438 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Annals of Oncology
2016 Journal of Clinical Oncology
2011 Annals of Oncology
2009 Annals of Oncology
2007 Annals of Oncology
2007 Journal of Clinical Oncology
2005 New England Journal of Medicine
2005 Annals of Oncology
2003 Journal of Clinical Oncology
2000 Journal of Clinical Oncology

Peers

Countries citing papers authored by Beat Thürlimann

Since Specialization

Citations

This map shows the geographic impact of Beat Thürlimann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beat Thürlimann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beat Thürlimann more than expected).

Fields of papers citing papers by Beat Thürlimann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beat Thürlimann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beat Thürlimann. The network helps show where Beat Thürlimann may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Beat Thürlimann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Beat Thürlimann Line = papers co-authored together Beat Thürlimann links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer Annals of Oncology ·Harold J. Burstein, Giuseppe Curigliano, Michael Gnant, Sibylle Loibl, Meredith M. Regan, Sherene Loi, (unknown), Philip Poortmans, David Cameron, Beat Thürlimann, William P. Weber, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2025	1
2	Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials JCO Precision Oncology ·Stephen J. Luen, محمد جميل محمد محسب خطاب, A Hillscher, Peter Savas, Roswitha Kammler, Patrizia Dell’Orto, Olivia Biasi, Alan S. Coates, Richard D. Gelber, Beat Thürlimann, Marco Colleoni, Gini F. Fleming, Prudence A. Francis, Meredith M. Regan, Giuseppe Viale, Sherene Loi	2025	1
3	Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?—Reply JAMA Oncology ·Jens Huober, Beat Thürlimann, Daniel Dietrich	2024	1
4	Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00 Clinical Cancer Research ·He Yachao, Mattia Rediti, David Venet, Samira Majjaj, Roswitha Kammler, Elisabetta Munzone, Lorenzo Gianni, Beat Thürlimann, Josef Hrudka, Marco Colleoni, Sherene Loi, Giuseppe Viale, Meredith M. Regan, Laurence Buisseret, Françoise Rothé, Christos Sotiriou	2023	7
5	Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial Cancer ·José Pablo Leone, Bernard F. Cole, Meredith M. Regan, Beat Thürlimann, Alan S. Coates, Manuela Rabaglio, Anita Giobbie‐Hurder, Richard D. Gelber, Bent Ejlertsen, Vernon Harvey, Patrick Neven, István Láng, Hervé Bonnefoi, Andrew Wardley, Aron Goldhirsch, Angelo Di Leo, Marco Colleoni, Inês Vaz-Luís, Nancy U. Lin	2020	5
6	Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data BMC Cancer ·Sabine Schmid, Dirk Klingbiel, Stefan Aebi, Aron Goldhirsch, Christoph Mamot, Elisabetta Munzone, Franco Nolè, C. Oehlschlegel, Olivia Pagani, Bernhard C. Pestalozzi, Christoph Rochlitz, Beat Thürlimann, Roger von Moos, Patrik Weder, Khalil Zaman, Thomas Ruhstaller	2019	7
7	Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98 Breast Cancer Research ·Kevin H. Kensler, Meredith M. Regan, Yujing J. Heng, Gabrielle M. Baker, Michael E. Pyle, Stuart J. Schnitt, Aditi Hazra, Roswitha Kammler, Beat Thürlimann, Marco Colleoni, Giuseppe Viale, Myles Brown, Rulla M. Tamimi	2019	90
8	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5 Journal of Clinical Oncology ·Mitch Dowsett, Ivana Šestak, Meredith M. Regan, Andrew Dodson, Giuseppe Viale, Beat Thürlimann, Marco Colleoni, Jack Cuzick	2018	110
9	Chemotherapy regimens in early breast cancer: major controversies and future outlook Expert Review of Anticancer Therapy ·Markus Joerger, Beat Thürlimann	2013	19
10	Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial Journal of Clinical Oncology ·Marianne Ewertz, Kathryn P. Gray, Meredith M. Regan, Bent Ejlertsen, Karen N. Price, Beat Thürlimann, Hervé Bonnefoi, John Forbes, Robert Paridaens, Manuela Rabaglio, Richard D. Gelber, Marco Colleoni, István Láng, Ian E. Smith, Alan S. Coates, Aron Goldhirsch, Henning T. Mouridsen	2012	102
11	Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? Annals of Oncology ·Markus Joerger, Beat Thürlimann, Jens Huober	2010	22
12	Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial Annals of Oncology ·Manuela Rabaglio, Zijie Sun, Karen N. Price, Monica Castiglione‐Gertsch, Hanne Hawle, Beat Thürlimann, Henning T. Mouridsen, Mario Campone, JF Forbes, Robert Paridaens, Marco Colleoni, Tadeusz Pieńkowski, Jean‐Marie Nogaret, István Láng, Ian Smith, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates	2009	133
13	Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer Annals of Oncology ·Guenther Gruber, Bernard F. Cole, Monica Castiglione‐Gertsch, Stig B. Holmberg, Jurij Lindtner, Rastko Golouh, J. Collins, Diana Crivellari, Beat Thürlimann, Edda Simoncini, Martin F. Fey, Richard D. Gelber, Alan S. Coates, Karen N. Price, Aron Goldhirsch, Giuseppe Viale, B.A. Gusterson	2008	26
14	Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial Journal of Clinical Oncology ·Henning T. Mouridsen, Aparna Keshaviah, Alan S. Coates, Manuela Rabaglio, Monica Castiglione‐Gertsch, Zhuoxin Sun, Beat Thürlimann, L. Mauriac, John Forbes, Robert Paridaens, Richard D. Gelber, Marco Colleoni, Ian Smith, Karen N. Price, Aron Goldhirsch	2007	93
15	Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Annals of Oncology ·Aron Goldhirsch, W. C. Wood, Richard D. Gelber, Alan S. Coates, Beat Thürlimann, Hans-Jörg Senn Hit paper breakdown →	2007	680
16	Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial Annals of Oncology ·L. Mauriac, Aparna Keshaviah, Marc Debled, Henning T. Mouridsen, John Forbes, Beat Thürlimann, R. Paridaens, Alain Monnier, István Láng, Andrew Wardley, Jean‐Marie Nogaret, RD Gelber, Monica Castiglione‐Gertsch, K.N. Price, Alan S. Coates, Ian Smith, Giuseppe Viale, Manuela Rabaglio, M. Wolf, Aron Goldhirsch	2007	106
17	The multidisciplinary meeting: An indispensable aid to communication between different specialities European Journal of Cancer ·Thomas Ruhstaller, Helen Roe, Beat Thürlimann, J. J. Nicoll	2006	211
18	Current Concepts of Treatment Strategies in Advanced or Recurrent Ovarian Cancer Oncology ·Marc Salzberg, Beat Thürlimann, 大同均, Daniel Fink, Christoph Rochlitz, Roger von Moos, Hans-Jörg Senn	2005	58
19	Guideline zur adjuvanten Systemtherapie (AST) des Mammakarzinoms der Frau Schweizerische Ärztezeitung ·О. В. Прокопчук, Beat Thürlimann, Monica Castiglione‐Gertsch, 都启玲, 近藤敦子, Yongje, Fabio Canova, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2003	3
20	Biochemical Markers of Bone Remodelling Oncology Research and Treatment ·H. Engler, Beat Thürlimann, 佘惟槟	1996	8

About Beat Thürlimann

Beat Thürlimann is a scholar working on Cancer Research, Oncology, Genetics, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 214 papers that have together received 17.9k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (118 papers), Estrogen and related hormone effects (70 papers), Cancer Treatment and Pharmacology (49 papers), HER2/EGFR in Cancer Research (47 papers), Advanced Breast Cancer Therapies (36 papers), Breast Lesions and Carcinomas (28 papers), Bone health and treatments (23 papers) and Cancer Risks and Factors (15 papers). The work is most often cited by research in Cancer Research (10.1k citations), Oncology (10.9k citations), Genetics (5.5k citations), Pathology and Forensic Medicine (3.0k citations) and Pulmonary and Respiratory Medicine (3.4k citations). Beat Thürlimann has collaborated with scholars based in Switzerland, United States and Italy. Frequent co-authors include Aron Goldhirsch, Richard D. Gelber, Alan S. Coates, Hans-Jörg Senn, W. C. Wood, Karen N. Price, Monica Castiglione‐Gertsch, Marco Colleoni, James N. Ingle and Meredith M. Regan. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer, The Breast and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact